Search

s / Can J Diabetes 36 (2012) S24eS76 S45 randomized treatment group and 22% of the randomized control group had HbA1c

Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind PlaceboControlled Trial. B. ZINMAN*, J. GERICH, J. BUSE, A. LEWIN, S. L. SCHWARTZ, P. RASKIN, P. M. HALE, M. ZDRAVKOVIC, L. BLONDE, University of Toronto, Canada; Rochester University Medical School, NY; North Carolina University Medical School, Chapel Hill, NC; National Research Institute, Los Angeles, CA; DGD Research, San Antonio, CA; Texas University, Dallas, TX; Novo Nordisk, Princeton, NJ, USA; Bagsvaerd, Denmark; Ochsner Medical Center, New Orleans, LA, USA This 26-week randomized trial compared the efficacy and safety of two doses of liraglutide (lira; 1.2 and 1.8 mg, OD) to placebo (plb) in patients with Type 2 DM on metformin 2 g (met; 1 g, BD) and rosiglitizone 8 mg (rosi; 4 mg, BD). Subjects were previously treated with 1 or more oral antidiabetic drugs (OADs). 533 subjects were randomized (mean age 55.1±10.2 years, mean BMI 33.5±5.2 kg/m, mean HbA1c 8.3±1.0%). All patients received run-in rosi and met therapy before being randomized to lira or lira plb. Lira 1.2 mg and 1.8 mg reduced HbA1c more than placebo (ANCOVA, p